Download App

Log in to access Online Inquiry
Company Overview More
Palisade Bio, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Its lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress caused by reduced blood flow to the intestine, infections, and surgery. The company was founded in 2005 and is based in Carlsbad, California.
CEO: Hallam Ph.D., Thomas M.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > PALI Palisade Bio > Detailed Quotes

PALI Palisade Bio

0.515+0.003+0.59%
Close 05/19 20:00 ET
High
0.530
Open
0.514
Turnover
26.60K
Low
0.504
Pre Close
0.512
Volume
51.89K
Market Cap
11.27M
P/E(TTM)
Loss
52wk High
4.570
Shares
21.88M
P/E(Static)
Loss
52wk Low
0.400
Float Cap
6.95M
Bid/Ask %
-53.85%
Historical High
792.000
Shs Float
13.49M
Volume Ratio
0.24
Historical Low
0.400
Dividend TTM
--
Div Yield TTM
--
P/B
2.35
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.39%
Amplitude
4.98%
Avg Price
0.512
Lot Size
1
Float Cap
6.95M
Bid/Ask %
-53.85%
Historical High
792.000
Shs Float
13.49M
Volume Ratio
0.24
Historical Low
0.400
Dividend TTM
--
P/B
2.35
Dividend LFY
--
Turnover Ratio
0.39%
Amplitude
4.98%
Avg Price
0.512
Lot Size
1
Price Forecast

No Data

News

Comment